Format

Send to

Choose Destination
Mult Scler Relat Disord. 2018 May;22:19-21. doi: 10.1016/j.msard.2018.02.029. Epub 2018 Feb 27.

Could antiretrovirals be treating EBV in MS? A case report.

Author information

1
Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, United States; Health Sciences & Technology, Harvard Medical School, Boston, MA, United States. Electronic address: ncd@mit.edu.
2
Health Sciences & Technology, Harvard Medical School, Boston, MA, United States; Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA, United States; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, United States. Electronic address: ere@mit.edu.
3
Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, United States. Electronic address: dhousman@mit.edu.

Abstract

We present the case of an HIV-negative patient clinically diagnosed with relapsing-remitting MS who achieved significant disease improvement on Combivir (zidovudine/lamivudine). Within months of treatment, the patient reported complete resolution of previously unremitting fatigue and paresthesiae, with simultaneous improvements in lesion burden detected by MRI. All improvements have been sustained for more than three years. This response may be related to the action of zidovudine as a known inhibitor of EBV lytic DNA replication, suggesting future directions for clinical investigation.

KEYWORDS:

Epstein-Barr virus; Multiple sclerosis

PMID:
29510325
PMCID:
PMC6100748
DOI:
10.1016/j.msard.2018.02.029
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center